The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 34, Issue 2, 2009, Pages 107-115

  Iida, Satofumi ^a   Kinoshita, Haruki ^a   Kawanishi, Takehiko ^a   Hayashi, Masahiro ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Japanese; PKPD; Population pharmacokinetics; Time above MIC

Indexed keywords

CEFTRIAXONE; ANTIINFECTIVE AGENT;

AGE; ANTIBIOTIC SENSITIVITY; ARTICLE; BODY WEIGHT; BOOTSTRAPPING; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; JAPANESE; MONTE CARLO METHOD; VALIDATION PROCESS; ADOLESCENT; ADULT; AGED; ASIAN; BACTERIUM; BIOLOGICAL MODEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; HUMAN; JAPAN; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; NONLINEAR SYSTEM; PROTEIN BINDING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BACTERIA; BODY WEIGHT; CEFTRIAXONE; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NONLINEAR DYNAMICS; PROTEIN BINDING; YOUNG ADULT;

EID: 68949092434     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191159     Document Type: Article

References (26)

1. Wise R., Gillett A.P., Andrews J.M., Bedford K.A. (1980): Ro 13-9904: A cephalosporin with a high degree of activity and broad ntibacterial activity: an in vitro comparative study. J. Antimicrob. Chemother., 6, 595-600.
2. Scully B.E., Fu K.P., Neu H.C. (1984): Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. Am. J. Med., 77, 112-116.
3. McNamara P.J., Trueb V. Stoeckel K. (1990): Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam. Biochem. Pharmacol., 40, 1247-1453.
4. Hayton W.L., Stoeckel K. (1986): Age-associated changes in ceftriaxone pharmacokinetics. Clin. Pharmacokinet., 11, 76-86.
5. Sheiner L.B., Beal S.L. (1981): Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J. Pharmacokinet. Biopharm., 9, 635-651.
6. Sheiner L.B., Beal S.L. (1980): Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm., 8, 553-571.
7. Sheiner L.B., Beal S.L. (1983): Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm., 11, 303-319.
8. Green B., Duffull S.B. (2004): What is the best size descriptor to use for pharmacokinetic studies in the obese? Br. J. Clin. Pharmacol., 58, 119-133.
9. Funaki T. (1999): Enterohepatic circulation model for population pharmacokinetic analysis. J. Pharm. Pharmacol., 51, 1143-1148.
10. Matsuzaki K., Shito K., Watabe E., Hasegawa M., Sato Y., Kobayashi I. (2005): Antibacterial activity of ceftriaxone against various clinical strains isolated in 2004. Jpn. J. Antibiot., 58, 283-289.
11. Craig W.A. (1995): Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis., 22, 89-96.
12. Cohen D., Appel G.B., Scully B., Neu H.C. (1983): Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob. Agents. Chemother., 24, 529-532.
13. Simon N., Dussol B., Sampol E., Purgus R., Brunet P., Lacarelle B., Berland Y., Bruguerolle B., Urien S. (2006): Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin. Pharmacokinet., 45, 493-501.
14. Ribbing J., Jonsson E.N. (2004): Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J. Pharmacokinet. Pharmacodyn., 31, 109-134.
15. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W.A. (1988): Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis., 158, 831-847.
16. Iwasawa T. (1985): Basic and clinical studies on Ceftriaxone in the field of otolaryngology. J. New Remedies & Clinics, S38 34
17. Hutagi Y., Kawane H., Kawanishi M., Watanabe M., Adachi M., Matsushime T., Scejima R. (1984): Clinical studies of ceftriaxone (Ro 13-9904) for respiratory tract infections. Chemotherapy (Tokyo), 32, 413-420. (Pubitemid 15215546)
18. Nakajima M., Nishijima N. (1984): Clinical phase I study of ceftriaxone (Ro 13-9904). Chemotherapy (Tokyo), 32, 178-196.
19. Yamasaku F., Suzuki Y. (1984): Basic and clinical studies on ceftriaxone (Ro 13-9904). Chemotherapy (Tokyo), 32, 371-379. (Pubitemid 15215542)
20. Fukuda O., Miyamura S., Inoue S., Maeyama M. (1984): Fundamental study on tissue distribution of ceftriaxone in the field of obstetrics and gynecology. Jpn. J. Antibiot., 37, 2416-2419.
21. Hongo M., Shimizu R., Sakae K., Hayashi S., Yoshinouchi M., Mitsui Y. (1984): Study on transfer of ceftriaxone into female genital organs. Jpn. J. Antibiot., 37, 2391-2396,
22. Miyakawa I., Taniyama K., Nagai K., Yasuda H., Mori N.. (1984): Pharmacokinetics of ceftriaxone in the peripheral venous serum, uterine arterial serum and intrapelvic genital organs. Jpn. J. Antibiot., 37, 2420-2426.
23. Saito A., Kato Y., Ishikawa K., Odagati E., Shinohara M., Tomizawa M., Nakayama I., Sato K. (1984): Studies on ceftriaxone (Ro 13-9904). Chemotherapy (Tokyo), 32, 197-211.
24. Yamaji T., Saito A., Shinada J., Omori M., Shiba T., Ihara H., Hojo T., Kaji M., Miyahara T., Ueda V. et al. (1984): Clinical studies on ceftriaxone (Ro 13-9904). Chemotherapy (Tokyo), 32, 259-278.
25. Hirabayashi K., Okada E. (1984): Fundamental and clinical study of ceftriaxone in the field of obstetrics and gynecology. Jpn. J. Antibiot., 37, 2384-2390.
26. Doko F. (1984): Basic and clinical studies of ceftriaxone in the field of obstetrics and gynecology. Jpn. J. Antibiot., 37, 2377-2383.